

04-19-05

IFW

CASE 4-30400B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 483667802 US
Express Mail Label NumberApril 18, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
O'REILLY ET AL.
APPLICATION NO: 10/633,114
FILED: AUGUST 1, 2003
FOR: CANCER TREATMENT WITH EPOTHILONES

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed October 8, 2003. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

German Patent DE195 42 968 A1 is substantially equivalent to U.S. Patent Publication Nos. 2001/034452 A1; 2004/087634 A1; and U.S. Patent Nos. 6,288,237 and 6,613,912.

German Patent DE 196 36 343 A1 is substantially equivalent to U.S. Patent Nos. 5,969,145; 6,043,372; and 6,156,905.


German Patent DE 197 16 231 A1 is substantially equivalent to U.S. Patent No.
6,348, 551.

German Patent DE 197 20 312 A1 is substantially equivalent to U.S. Patent No.
6,020,315

The Examiner is requested to consider the foregoing information in relation to this
application and indicate that each reference was considered by returning a copy of the initialed
PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Oona A. Jackson
Attorney for Applicants
Reg. No. 48,152

Date: 4/18/05

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. ON/4-30400B	Application No. 10/633,114
Information Disclosure Statement by Applicant (Use several sheets if necessary)			
(37 CFR §1.98(b))		Applicant Reilly et al.	Group Art Unit 1614
		Filing Date August 1, 2003	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,716,939	02/10/1998	Lundy et al.			
	AB	5,969,145	10/19/1999	Schinzer et al.			
	AC	6,020,315	02/01/2000	Bosslet et al.			
	AD	6,043,372	03/28/2000	Schinzer et al.			
	AE	6,121,029	09/19/2000	Schupp et al.			
	AF	6,156,905	12/05/2000	Schinzer et al.			
	AG	6,288,237	09/11/2001	Hoefle et al.			
	AH	6,242,469	06/05/2001	Danishefsky et al.			
	AI	6,284,781	09/04/2001	Danishefsky et al.			
	AJ	6,300,355	10/09/2001	Danishefsky et al.			
	AK	6,348,551	02/19/2002	Fürstner et al.			
	AL	6,350,878	02/26/2002	Altmann et al.			
	AM	6,369,234	04/09/2002	Danishefsky et al.			
	AN	6,380,394	04/30/2002	Nicolaou et al.			
	AO	6,441,186	08/27/2002	Nicolaou et al.			
	AP	6,605,726	08/12/2003	Multzer et al.			
	AQ	6,613,912	09/02/2003	Hoefle et al.			
	AR	6,660,758	12/09/2003	Nicolaou et al.			
	AS	6,828,340	12/07/2004	Danishefsky et al.			
	AT	6,831,076	12/14/2004	Hoefle et al.			
	AU	US 2001/034452 A1	10/25/2001	Hoefle et al.			
	AV	US 2003/0203876 A1	10/30/2003	Hoogevest			
	AW	US 2003/0203938 A1	10/30/2003	Nicolaou et al.			
	AX	US 2003/0220295 A1	11/27/2003	Vite et al.			
	AY	US 2004/0127432 A1	07/01/2004	Nicolaou et al.			
	AZ	US 2004/0142990 A1	07/22/2004	Hofmann et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. ON/4-30400B	Application No. 10/633,114
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant O'Reilly et al.	
		Filing Date August 1, 2003	Group Art Unit 1614

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AAA	US 2004/0176429 A1	09/09/2004	Li et al.			
	ABB	US 2004/0253697 A1	12/16/2004	Julien et al.			
	ACC	US 2004/0260098 A1	12/23/2004	Danishefsky et al.			
	ADD	US 2004/087634 A1	05/06/2004	Hoefle et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. ON/4-30400B	Application No. 10/633,114
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant O'Reilly et al.	
		Filing Date August 1, 2003	Group Art Unit 1614
(37 CFR §1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AEE	DE 197 01 758 A1	07/23/1998	Germany (Abstract)				
	AFF	DE 197 13 970 A1	10/08/1998	Germany (Abstract)				
	AGG	DE 197 26 627 A1	12/24/1998	Germany (Abstract)				
	AHH	DE 198 21 954 A1	11/19/1998	Germany (Abstract)				
	AII	EP 0 941 089 B1	05/16/2001	Europe				
	AJJ	WO 98/08849	03/05/1998	WIPO				
	AKK	WO 98/22461	05/28/1998	WIPO				
	ALL	WO 99/42602	08/26/1999	WIPO				
	AMM	WO 99/43653	09/02/1999	WIPO				
	ANN	WO 99/59985	11/25/1999	WIPO				
	AOO	WO 99/66028	12/23/1999	WIPO				
	APP	WO 99/67252	12/29/1999	WIPO				
	AQQ	WO 99/67253	12/29/1999	WIPO				
	ARR	WO 00/00485	01/06/2000	WIPO				
	ASS	WO 00/31247	06/02/2000	WIPO				
	ATT	WO 01/83800	08/11/2001	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AUU	Avila, "The use of microtubule poisons on tumor cells," <i>Cancer Journal</i> , 10(6):315-318 (1997)
	AVV	Blasius et al., "Für Wissenschaft und Praxis," <i>Deutsche Apotheker Zeitung</i> , 138(46):54-69 (1998)
	AWW	Blum et al., "In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry," <i>Rapid Commun. Mass Spectrom.</i> , 15:41-49 (2001)
	AXX	Bollag et al., "Epothilone, a new structural class of microtubule stabilizer," <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , Vol. 36, Abstract 2711 (1995)
	AYY	Brandt et al., "Epothilones A and B are potent inducers of apoptosis," <i>Proceedings of the American Association for Cancer Research</i> , 39:140, Abstract 957 (1998)
	AZZ	Buck et al., "Epothilones, a New Class of Microtubule-Stabilizing Agents with a Taxol-like Mechanism of Action," <i>Chemtracts—Organic Chemistry</i> , 11(9):671-677 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. ON/4-30400B	Application No. 10/633,114
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant O'Reilly et al.	
		Filing Date August 1, 2003	Group Art Unit 1614
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AAAA	Chou et al., "Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel," <i>Proc. Natl. Acad. Sci. USA</i> , 95:15798-15802 (1998)
	ABBB	Colburn et al., "Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia," <i>Investigational New Drugs</i> , 21:109-111 (2003)
	ACCC	"Epothilones Active Against Tumors by Blocking Cell Division," <i>Cancer Weekly</i> , pp. 22-23 (August 4, 1997)
	ADDD	Gensthaler, "Von Antitumorsubstanzen bis zu Pulverinhalatoren und Suramin," <i>Pharmazeutische Zeitung</i> , 143(49):42-45 (1998)
	AEEE	Hamel, "Antimitotic Natural Products and Their Interactions with Tubulin," <i>Medicinal Research Reviews</i> , 16(2):207-231 (1996)
	AFFF	Houlder, "Bones of a new cancer treatment," <i>The Financial Times</i> , p. 16 (May 15, 1997)
	AGGG	Kowalski et al., "Comparison of Novel Microtubule Polymerizing Agents, Discodermolide and Epothilone A/B, with Taxol," <i>Molecular Biology of the Cell</i> , Vol. 6, Abstract 2137 (1995)
	AHHH	Lavelle, "What's new about new tubulin/microtubules binding agents?" <i>Exp. Opin. Invest. Drugs</i> , 4(8):771-775 (1995)
	AIII	"Microbes create class of cancer fighters," <i>Biotechnology Newswatch</i> , p. 10 (August 4, 1997)
	AJJJ	"Neue krebshemmende Substanz entdeckt," <i>Lebensmittel & Biotechnologie</i> , 13(3):102 (1996)
	AKKK	Schackert, "Neue Hoffnung durch Epothilone," <i>Deutsche Apotheker Zeitung</i> , 137(47):37-38 (1997)
	ALLL	Schinzer et al., "Epothilone: neue Wirkstoffe gegen Krebs," <i>Spektrum der Wissenschaft</i> , pp. 38-43 (August 1997)
	AMMM	Schultz et al., "Bringing biological solutions to chemical problems," <i>Proc. Natl. Acad. Sci. USA</i> , 90:14590-14951 (1998)
	ANNN	Service, "Tumor-Killer Made; How Does It Work?" <i>Science</i> , 274(5295):2009 (1996)
	AOOO	Wessjohann, "Epothilones: Promising Natural Products with Taxol-Like Activity," <i>Angew. Chem. Int. Ed. Engl.</i> , 36(7):715-718 (1997)
	APPP	Woo et al., "Phase I Targeted Systemic Exposure Study of Paclitaxel in Children with Refractory Acute Leukemias," <i>Clinical Cancer Research</i> , 5:543-549 (1999)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	